These observations suggest that, while combination of PIT and Nal–IRI is more effective in reducing cancer cell viability compared to their monotherapies, the co-packaging of PIC and irinotecan in a single nanoformulation might not be required in low EGFR-expressing tumors. Here, EGFR is linked to cancer.